Finally, VISTA and PD-1 pathways were increased following CTLA-4 blockade in patients suffering from prostate cancer indicating that the manipulation of VISTA also acts in synergy and non-redundant to CTLA-4 blockade [527]. This evidence concerns the gene CTLA4 and prostate carcinoma.